Search Results
., Vollmer, W. M., et al.: International variation in the prevalence of COPD (the BOLD Study): a population-based prevalence study. Lancet, 2007, 370 (9589), 741–750. 5
pulmonary disease. In: Murin S., Silvestri G. (eds.): Clinics in Chest Medicine, 2000, 21 , 87–94. Vadász I.: COPD – újabb ismeretek, bővülő lehetőségek. Orvostovábbképző Szemle, 2006, 13 , 13
2006 COPD exacerbations 2: aetiology Thorax 61 3 250 – 258 . 3. J.C. Hogg
improves exercise tolerance from the first dose in patients with COPD: the GLOW3 trial . Int. J. Chron. Obstruct. Pulmon. Dis. 7 , 503 – 513 ( 2012 ) 4. Beeh KM
In a recent trial we have assessed fractional exhaled nitric oxide (FENO) in a cohort of patients with an acute exacerbation of chronic obstructive pulmonary disease (COPD). In the current study we have retrospectively investigated the frequency of severe hospitalization-associated exacerbations in the same cohort over 3 years after the initial FENO measurement. A total of 58 COPD patients were enrolled and allocated either into the low (< 27 ppb) or the high (≥ 27 ppb) FENO group depending on their FENO level at exacerbation. Beside the annual rate of exacerbations, sputum culture results and the frequency of antibiotic treatments were also analyzed during the follow-up. Both the number of exacerbations per patient-year and the hospitalization days due to exacerbations were significantly increased in patients from the low FENO group compared to those from the high FENO group. Sputum samples derived from patients in the low FENO group were more frequently indicative of a bacterial infection compared to those obtained from the other subgroup. Also, the frequency of antibiotic treatments was significantly increased in subjects from the low FENO group. Results of this pilot study suggest that COPD patients have diverse risks for future exacerbations depending on their FENO levels at exacerbation.
Introduction Chronic obstructive pulmonary disease (COPD) is a progressive inflammatory lung disease that causes obstructed airflow limitation from the lungs. COPD is currently the third leading cause of death worldwide
–943. 2 Böszörményi NGy. COPD. [COPD.] Korányi Bull. 2019; 1: 24–31. [Hungarian] 3 Braido F, Bagnasco D, Scichilone N, et al. Biomarkers in obstructive respiratory
Introduction Chronic obstructive pulmonary disease (COPD) is a progressive inflammatory condition of the lungs characterized by pulmonary symptoms, such as shortness of breath and/or cough, and extra-pulmonary manifestations, such as cachexia and
Introduction The pathogenesis and clinical manifestations of Chronic Obstructive Pulmonary Disease (COPD) appear typically as pulmonary inflammation and structural abnormalities; yet in several cases, systemic lesions may also be present [ 1
Obstruktív tüdőbetegségek súlyosbodása SARS-CoV-2-fertőzés hatására a marosvásárhelyi Pulmonológiai Klinika beteganyagában
Exacerbation of obstructive pulmonary diseases by SARS-CoV-2 infection in patients treated in the Pulmonology Clinic of Târgu Mures
: 113–122. 6 Leung JM, Niikura M, Yang CW, et al. COVID-19 and COPD. Eur Respir J. 2020; 56: 2002108. 7
